Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
Arasappan A, Njoroge FG, Chan TY, Bennett F, Bogen SL, Chen K, Gu H, Hong L, Jao E, Liu YT, Lovey RG, Parekh T, Pike RE, Pinto P, Santhanam B, Venkatraman S, Vaccaro H, Wang H, Yang X, Zhu Z, Mckittrick B, Saksena AK, Girijavallabhan V, Pichardo J, Butkiewicz N, Ingram R, Malcolm B, Prongay A, Yao N, Marten B, Madison V, Kemp S, Levy O, Lim-Wilby M, Tamura S, Ganguly AK. Arasappan A, et al. Among authors: parekh t. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4180-4. doi: 10.1016/j.bmcl.2005.06.091. Bioorg Med Chem Lett. 2005. PMID: 16087332
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
Venkatraman S, Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu YT, Lovey R, Hendrata S, Huang Y, Pan W, Parekh T, Pinto P, Popov V, Pike R, Ruan S, Santhanam B, Vibulbhan B, Wu W, Yang W, Kong J, Liang X, Wong J, Liu R, Butkiewicz N, Chase R, Hart A, Agrawal S, Ingravallo P, Pichardo J, Kong R, Baroudy B, Malcolm B, Guo Z, Prongay A, Madison V, Broske L, Cui X, Cheng KC, Hsieh Y, Brisson JM, Prelusky D, Korfmacher W, White R, Bogdanowich-Knipp S, Pavlovsky A, Bradley P, Saksena AK, Ganguly A, Piwinski J, Girijavallabhan V, Njoroge FG. Venkatraman S, et al. Among authors: parekh t. J Med Chem. 2006 Oct 5;49(20):6074-86. doi: 10.1021/jm060325b. J Med Chem. 2006. PMID: 17004721
P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
Arasappan A, Njoroge FG, Chen KX, Venkatraman S, Parekh TN, Gu H, Pichardo J, Butkiewicz N, Prongay A, Madison V, Girijavallabhan V. Arasappan A, et al. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3960-5. doi: 10.1016/j.bmcl.2006.05.022. Epub 2006 May 30. Bioorg Med Chem Lett. 2006. PMID: 16730985
Design and implementation of optics for the experiment for cryogenic large-aperture intensity mapping (EXCLAIM).
Essinger-Hileman T, Chmaytelli D, Oxholm T, Parekh T, Siebert G, Switzer ER, Watson J, Barlis A, Barrentine EM, Beeman J, Chung C, Cursey P, Dahal S, Datta R, Ehsan N, Glenn J, Golec J, Lennon A, Lowe LN, McMahon J, Rahmani M, Timbie P, Tretheway B, Tucker C, Volpert C, Wollack EJ. Essinger-Hileman T, et al. Among authors: parekh t. Rev Sci Instrum. 2025 Jan 1;96(1):014503. doi: 10.1063/5.0246814. Rev Sci Instrum. 2025. PMID: 39807964
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Ye JC, Biran N, Nair S, Lin X, Qi K, Londhe A, Ammann E, Renaud T, Kane C, Parekh T, Gray K, Peterson S, Costa LJ. Ye JC, et al. Among authors: parekh t. Clin Lymphoma Myeloma Leuk. 2024 Aug 13:S2152-2650(24)00295-7. doi: 10.1016/j.clml.2024.08.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39271448
143 results